Skip to main content

Table 2 Immediate adverse events in 124 infusions

From: Real world safety of CT-P10 (anti-CD 20 monoclonal antibodies biosimilar) in rheumatic and autoimmune diseases

Adverse events (N = 15 events)

Number of events (%)

Infusion reaction

 

 Grade 1

4 (3.2)

 Grade 2

2 (1.6)

 Grade 3

0 (0.0)

 Grade 4

0 (0.0)

 Grade 5

0 (0.0)

Skin

 

 Rash

0 (0.0)

 Flushing

4 (3.2)

 Itching

1 (0.8)

 Mucosa (angioedema)

0 (0.0)

Respiratory

 

 Shortness of breath

4 (3.2)

 Wheeze

0 (0.0)

 Stridor

0 (0.0)

 Cough

0 (0.0)

 Hypoxemia

0 (0.0)